In a set of newly released presentations, officials from the US Food and Drug Administration (FDA) explain changes to the agency's biomarker qualification program and detail early opportunities for ...

Interest in biomarkers has exploded in recent years, driven by improvements in data collection and analysis, burgeoning interest in personalized medicine, and efforts to increase the success rate for ...

Protein biomarkers increasingly play a vital role in advancing health research, driving drug development, and improving clinical outcomes. The close connection between protein biomarkers and human ...

Cancer immunotherapy has significantly changed the clinical management of multiple malignancies, yet substantial challenges remain in identifying which ...

Every decision in drug development carries weight. The right biomarker insights can make those decisions more confident and data-driven. In this white paper, experts from AstraZeneca, Johnson & ...

Drug development involves significant risk and expense. With average development costs topping $1 billion per approved medicine and stubbornly high failure rates, pharmaceutical leaders are ...

Despite their importance, a significant number of biomarker strategies fail because they are added too late, are not feasible in real clinical settings, or are poorly aligned with clinical endpoints.

This activity was supported by contracts between the National Academy of Sciences and Acadia Pharmaceuticals; Alzheimer’s Association; American Brain Coalition; American Neurological Association; ...

ViewsML, a company building the computational layer for biomarker discovery by transforming tissue analysis from a lab process into software, today announced the completion of an oversubscribed $4.9M ...